| Genetics News:
Stem Cell Therapy International, Inc.: Stem Cell Therapy International Names Eminent Stem Cell Research Scientist Igor Katkov to Its Medical and Scientific Advisory Board
TAMPA, FL (MARKET WIRE) Stem Cell Therapy International, Inc. (OTC: SCII), a leading company in the field of research and development of stem cell transplantation therapy and regenerative medicine, today appointed Igor Katkov, Ph.D., to its Medical and Scientific Advisory Board. Dr. Katkov holds an academic position at the University of California San Diego (UCSD) and he is a member of The Burnham Institute Stem Cell Center in La
Stem Cell Therapy International Names Eminent Stem Cell Research Scientist Igor Katkov to Its Medical and Scientific Advisory Board
Stem Cell Therapy International, Inc. (OTC: SCII), a leading company in the field of research and development of stemcell transplantation therapy and regenerative medicine, today appointedIgor Katkov, Ph.D., to its Medical and Scientific Advisory Board. Dr.Katkov holds an academic position at the University of California San Diego(UCSD) and he is a member of The Burnham Institute Stem Cell Center in LaJolla, CA. His expertise combines a knowledge of physics, biology,biochemistry and stem cell biology. Since 1988, he has been a scientificconsultant to the Institute for Cryobiology and Cryomedicine in Kharkov,Ukraine. He has gained unique experience in working with adult, cord blood,and embryonic stem cells, and is an active consultant in organizing a cordblood stem cell bank in St. Petersburg, in the Russian Federation.
Frist Supports Federal Funds for Embryonic Stem Cell Research
The Media Cynic reports that Senator Bill Frist has decided to change his position on stem cell research and now plans to support federal funding for embryonic stem cell research. Frist's position is now against President Bush's controversial and highly restrictive policy. President Bush has already threatened to veto a new stem cell bill which passed in the House that promises federal funding of stem cell research. So, it is a promising development that the Senate might pass a bill that allows federal dollars to be put towards this promising research and allows more embryonic stem cell lines to be used. Unfortunately, President Bush could veto the bill -- as he has already threatened to do. This news report contains the full text of Frist's statement.
Genaera Completes Special Protocol Assessment with FDA for EVIZON and Geron Updates on Human Embryonic Stem Cell Programs at International Society for Stem Cell Research Meeting
City of Industry, CA --(www.FinancialNewsUSA.com)-- 06/27/2005 - Biotechnology industry news provided by Financial News USA (OTC: FNWU). Genaera Corporation (Nasdaq: GENR) today announced that it h
|